Nasal Spray Cardiovascular New Drug Etripamil Phase III Results Positive
ADC评论
October 19, 2022
On October 17, Milestone Pharmaceuticals announced positive data from the Phase III RAPID study of the inhaled calcium channel blocker Etripamil in the treatment of
